<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127712</url>
  </required_header>
  <id_info>
    <org_study_id>0407-16</org_study_id>
    <nct_id>NCT00127712</nct_id>
  </id_info>
  <brief_title>Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery</brief_title>
  <official_title>Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the medication amiodarone decreases the incidence of
      atrial fibrillation (AF) following non-cardiac open-chest surgery. Their specific aims are
      to:

        -  Determine the effectiveness of amiodarone for the prevention of AF following non-cardiac
           open-chest surgery;

        -  Determine the influence of the prevention of AF following non-cardiac thoracic surgery
           on post-surgical duration of stay in the Intensive Care Unit (ICU); post-surgical
           duration of stay in a hospital unit that employs cardiac monitoring; and duration of
           post-surgical hospital stay; and

        -  Determine the safety of amiodarone for the prevention of AF following non-cardiac
           open-chest surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thousands of patients undergo major non-cardiac open-chest surgery in the United States each
      year. These surgeries most often consist of lung surgery, in which one lobe of the lung is
      removed (lobectomy) or the entire lung is removed (pneumonectomy).

      A major complication of these non-cardiac open-chest surgeries is the occurrence of an
      irregular heartbeat known as atrial fibrillation (AF), which develops in up to 40% of
      patients undergoing these procedures. AF is characterized by rapid, irregular, chaotic
      beating of the two smaller chambers of the heart (the atria), leading to rapid, irregular
      beating of the two larger chambers (the ventricles). The average time to occurrence of
      post-surgical AF is 2-3 days following surgery. AF occurring following major non-cardiac
      open-chest surgery can result in extremely rapid heart rates, as fast as 150-200 beats per
      minute, and may be associated with serious consequences, including severely low blood
      pressure and potentially debilitating stroke. Further, the risk of death following
      non-cardiac open-chest surgery is significantly higher in patients who develop AF compared
      with those who do not. Therefore, the occurrence of this irregular heartbeat following
      non-cardiac open-chest surgery is associated with severe, potentially life-threatening
      consequences. Prevention of this irregular heartbeat in these patients may therefore be very
      important.

      Amiodarone is a medication that is known to be effective for prevention and treatment of AF
      that occurs in patients who have not undergone surgery. In addition, amiodarone has been
      shown to be effective for prevention of AF following open-chest heart surgery. However, the
      use of medications for prevention of AF following non-cardiac open-chest surgery has not been
      well studied, and amiodarone has not been studied in a controlled trial for the prevention of
      AF in patients undergoing these procedures. In addition, amiodarone is associated with side
      effects, and it is important to determine the safety of this medication when used in this
      patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Atrial Fibrillation Requiring Treatment</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Atrial Fibrillation Lasting Longer Than 30 Seconds</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit Stay</measure>
    <time_frame>Duration of hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Duration of hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group receive no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <arm_group_label>Amiodarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females over the age of 40

          -  Scheduled to undergo pneumonectomy or lobectomy

        Exclusion Criteria:

          -  History (hx) of atrial fibrillation

          -  Prior severe side effects from amiodarone

          -  Elevated liver enzymes &gt;3 times the upper limit of normal (UNL)

          -  QTc interval &gt; 450 ms

          -  Receiving class Ia or class III antiarrhythmics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James E Tisdale, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacy Practice- School of Pharmacy and Pharmacal Sciences- Purdue University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA. A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg. 2009 Sep;88(3):886-93; discussion 894-5. doi: 10.1016/j.athoracsur.2009.04.074.</citation>
    <PMID>19699916</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2005</study_first_posted>
  <results_first_submitted>March 2, 2010</results_first_submitted>
  <results_first_submitted_qc>March 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2010</results_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Purdue University</investigator_affiliation>
    <investigator_full_name>James E. Tisdale</investigator_full_name>
    <investigator_title>Professor and Interim Head, Dept of Pharmacy Practice, Purdue University and Adjunct Professor, School of Medicine, Indiana University</investigator_title>
  </responsible_party>
  <keyword>amiodarone</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>surgical procedures, thoracic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amiodarone</title>
          <description>Determine if amiodarone is effective for prevention of atrial fibrillation ater pulmonary resection surgery</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of GI access to continue</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amiodarone</title>
          <description>Determine if amiodarone is effective for prevention of atrial fibrillation ater pulmonary resection surgery</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Control group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="8"/>
                    <measurement group_id="B2" value="63" spread="9"/>
                    <measurement group_id="B3" value="62" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Atrial Fibrillation Requiring Treatment</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone</title>
            <description>Determine if amiodarone is effective for prevention of atrial fibrillation ater pulmonary resection surgery</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Atrial Fibrillation Requiring Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit Stay</title>
        <time_frame>Duration of hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone</title>
            <description>Determine if amiodarone is effective for prevention of atrial fibrillation ater pulmonary resection surgery</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit Stay</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="0" upper_limit="1416"/>
                    <measurement group_id="O2" value="84" lower_limit="0" upper_limit="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Atrial Fibrillation Lasting Longer Than 30 Seconds</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone</title>
            <description>Determine if amiodarone is effective for prevention of atrial fibrillation ater pulmonary resection surgery</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Atrial Fibrillation Lasting Longer Than 30 Seconds</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>Duration of hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone</title>
            <description>Determine if amiodarone is effective for prevention of atrial fibrillation ater pulmonary resection surgery</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="59"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amiodarone</title>
          <description>Determine if amiodarone is effective for prevention of atrial fibrillation ater pulmonary resection surgery</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James E. Tisdale</name_or_title>
      <organization>Purdue University</organization>
      <phone>317-613-2315 ext 306</phone>
      <email>jtisdale@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

